Vivani Medical, Inc. (VANI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated October 26, 2025, details a capital raise event for Vivani Medical, Inc. The company executed two concurrent equity transactions: a private placement and a registered direct offering. The filing was signed on October 28, 2025, by Donald Dwyer, Chief Business Officer.
Key Financial Metrics and Transaction Details
- Private Placement: Sale of 3,703,703 shares to an entity affiliated with Chairman Gregg Williams at $1.62 per share, generating gross proceeds of approximately $6.0 million.
- Registered Direct Offering: Sale of 6,000,000 shares via ThinkEquity LLC, generating gross proceeds of approximately $9.7 million before fees.
- Total Gross Proceeds: Approximately $15.7 million combined from both transactions.
- Offering Costs: The Registered Offering includes a 7.0% cash fee to the placement agent and reimbursement of up to $125,000 for legal and reimbursable expenses. No fees were incurred for the private placement.
- Lock-Up Agreements: Directors and officers agreed to a 60-day lock-up period from the closing of the Registered Offering.
Material Changes
The primary material change is the significant increase in the company's cash position through the issuance of 9,703,703 new shares of common stock. The filing does not provide comparative financial data (revenue, profit, or margins) for prior periods as this is a transaction-specific report rather than a periodic financial statement.
Outlook, Risks, and Contingencies
The company utilized Rule 506 of Regulation D for the private placement and a shelf registration statement (Form S-3) for the registered direct offering. The filing notes that the private placement shares are unregistered and subject to resale restrictions. No specific forward-looking guidance or operational outlook was provided in this text, other than the execution of the capital raise.
Key Facts for Investor Verification
- Verify the final closing date and net proceeds after deducting the 7.0% placement fee and expenses from the $9.7 million registered offering.
- Confirm the dilution impact of the 9,703,703 newly issued shares on existing shareholders.
- Review the full Share Purchase Agreement (Exhibit 10.1) and Placement Agency Agreement (Exhibit 10.2) for additional covenants or conditions.
- Monitor the 60-day lock-up expiration for directors and officers to assess potential near-term selling pressure.